Soligenix Inc. (NASDAQ: SNGX) recently provided an update on the progress of its Phase 3 trial for HyBryte(TM), a novel treatment for cutaneous T-cell lymphoma (CTCL), during an investment webinar. The webinar, hosted by Allele Capital, featured insights from Dr. Christopher Schaber and Dr. Christopher Pullion, who discussed the encouraging interim results from an investigator-initiated study at the University of Pennsylvania. Among the first eight patients who completed 18 weeks of treatment, 75% showed a greater than 50% reduction in disease severity, signaling potential breakthroughs in CTCL treatment.
CTCL is a rare form of non-Hodgkin's lymphoma that primarily affects the skin, with early-stage mycosis fungoides accounting for nearly 90% of cases. HyBryte(TM), a topical therapy activated by visible light, targets these lesions directly, offering a promising alternative to current treatments. The company anticipates top-line results from the Phase 3 trial in the second half of 2026, which could mark a significant advancement in the management of this challenging condition.
The development of HyBryte(TM) underscores Soligenix's commitment to addressing rare diseases and unmet medical needs. With CTCL affecting a small but significant patient population, the success of HyBryte(TM) could revolutionize treatment options, providing hope for those with limited alternatives. The interim results not only highlight the therapy's potential efficacy but also its importance in the broader context of oncology and rare disease research.
For more information on Soligenix's developments, visit https://ibn.fm/SNGX.
